Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph.D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Q2 2026 · $179.0MThe company’s own SEC segment disclosure.
- North America$121.0M68%
- Latin America$51.0M28%
- Asia Pacific$7.0M4%
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $214M in Q2 2026 (quarter ended June 30, 2026), up 28% from the same quarter a year earlier. That came with net loss of $92M. For the full year FY2025, revenue was $673M (+20% year on year) and net income −$575M. Its largest region in 2026-Q2 was North America at $121M, 68% of the disclosed total, just ahead of Latin America at 28%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.